Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “hold” rating reissued by Numis Securities Ltd in a research note issued on Monday. They currently have a GBX 1,000 ($16.59) price objective on the stock. Numis Securities Ltd’s price objective would indicate a potential downside of 4.12% from the stock’s previous close.

Smith & Nephew plc (LON:SN) opened at 1051.00 on Monday. Smith & Nephew plc has a 52 week low of GBX 737.50 and a 52 week high of GBX 1136.00. The stock has a 50-day moving average of GBX 1037. and a 200-day moving average of GBX 978.5. The company’s market cap is £9.396 billion.

A number of other firms have also recently commented on SN. Analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday. They now have a GBX 1,230 ($20.41) price target on the stock. Separately, analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday, August 26th. They now have a GBX 920 ($15.27) price target on the stock. Finally, analysts at Morgan Stanley downgraded shares of Smith & Nephew plc to an “equal weight” rating in a research note on Friday, August 15th. They now have a GBX 1,026 ($17.03) price target on the stock, up previously from GBX 980 ($16.26). Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of GBX 987.41 ($16.39).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with Analyst Ratings Network's FREE daily email newsletter.